Table 1:
Comparison of Baseline Demographic and Clinical Characteristics of the Study Population by Frailty Status
| Variable | Robust | Pre-Frail | Frail | P value |
|---|---|---|---|---|
|
| ||||
| N | 189 | 168 | 232 | |
|
| ||||
| Age, median (IQR) | 68 (64–74) | 69 (64–74) | 70 (65–75) | .37 |
|
| ||||
| Age category | .47 | |||
| - 60–65 | 66 (34.9%) | 50 (30.1%) | 62 (27%) | |
| -66–70 | 45(23.8%) | 40 (24.1%) | 55 (23.9%) | |
| - >70y | 78 (41.3%) | 76 (45.8%) | 113 (49.1%) | |
|
| ||||
| Sex | .76 | |||
| - Male | 104 (55%) | 88 (52.4%) | 130 (56%) | |
| - Female | 85 (45%) | 80 (47.6%) | 102 (44%) | |
|
| ||||
| Race | .01 | |||
| - White/Caucasian | 151 (80.3%) | 123 (74.6%) | 151 (65.7%) | |
| - Black/African-American | 32 (17%) | 38 (23%) | 76 (33.0%) | |
| - Hispanic | 15 (2.7%) | 4 (2.4%) | 3 (1.3%) | |
| - Unknown | 1 | 2 | 0 | |
|
| ||||
| Cancer Stage | .04 | |||
| - Stage I | 15 (7.9%) | 13 (7.8%) | 23 (10%) | |
| - Stage II | 32 (16.9%) | 34 (20.5%) | 38 (16.5%) | |
| - Stage III | 68 (36%) | 44 (26.5%) | 50 (21.7%) | |
| - Stage IV | 74 (39.2%) | 75 (45.2%) | 120 (52%) | |
| - Unknown | 0 | 2 | 1 | |
|
| ||||
| Cancer Stage | .04 | |||
| - Colorectal | 66 (34.9%) | 55 (32.7%) | 55 (23.7%) | |
| - Pancreatic | 45 (23.8%) | 33 (19.6%) | 78 (33.6%) | |
| - Hepatobiliary | 32 (16.9%) | 33 (19.6%) | 39 (16.8%) | |
| - Gastroesophageal | 20(10.6%) | 21 (12.5%) | 19 (8.2%) | |
| - Other GI cancersa | 26 (13.8%) | 26 (15.5%) | 41 (17.7%0 | |
|
| ||||
| Line of Therapy | .01 | |||
| - 1st line | 165 (91.7%) | 137 (87.3%) | 178 (80.9%) | |
| - 2nd line and beyond | 15 (8.3%) | 20 (12.7%) | 42 (19.1%) | |
a
Other GI includes Anal cancer (13), Appendiceal Cancer (7), Gastrointestinal stromal tumor (17), Neuroendocrine carcinoma (51), and GI not otherwise specified (5)